Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 21 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Kidney Neoplasms 5 von Hippel-Lindau Disease 4 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Fulvestrant 127 Trastuzumab 117 Paclitaxel 113 Letrozole 109 pembrolizumab 81 palbociclib 76 pertuzumab 75 Capecitabine 74 Anastrozole 72 Cyclophosphamide 70 Carboplatin 67 abemaciclib 65 exemestane 63 Tamoxifen 63 ribociclib 61 trastuzumab deruxtecan 57 Specimen Handling 51 Surveys and Questionnaires 50 Radiotherapy 50 Docetaxel 49 Magnetic Resonance Spectroscopy 48 Blood Specimen Collection 42 olaparib 40 Standard of Care 36 Biopsy 33 sacituzumab govitecan 32 130-nm albumin-bound paclitaxel 32 Exercise 30 Doxorubicin 30 eribulin 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × belzutifan × 1 year × Clear all

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡